AVAC's report identifies five priority issues that need attention now, including:
1. Ensure that current clinical trials have the best chance of providing results: Clinical trials now underway in Thailand, Africa, Latin American and the U.S. could establish the safety and effectiveness of PrEP, but only if these trials produce clear answers. Trial sponsors, regulatory agencies and the global health community must work together to ensure that these studies are supported to produce the data needed to determine next steps on the possible use of PrEP.
2. Identify and invest in additional research: A plan for launching additional studies - including studies on the safety and efficacy on intermittent PrEP dosing, bridging studies in additional populations, and safety and efficacy of other candidates - is needed now and will require additional funding.
3. Plan now for optimal use of PrEP: A plan of action for using PrEP to maximum public health impact should be developed now. This plan should address the issues set out in a Lancet paper of July 2007, which called for assessing appropriate settings and populations for PrEP use, determining what level of efficacy would warrant widespread delivery and determining where targeted vs. more generalized delivery would be more appropriate.
4. Prepare for global procurement and delivery of PrEP: Plans for PrEP delivery must include a well-planned and resourced campaign to deliver PrEP, an understanding of which global funders will pay for PrEP, plans for rollout, and guidance and support similar to that implemented for male circumcision.
5. Provide adequate financing: Underinvestment in PrEP is hampering progress and must be corrected. Government and private funders committed to global health must step forward now to ensure that PrEP research is fully funded.
AVAC's Anticipating and Understanding Results series provides timely
analysis of trials of new HIV prevention op
|SOURCE AIDS Vaccine Advocacy Coalition|
Copyright©2008 PR Newswire.
All rights reserved